Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
Merit Medical Systems, Inc. (MMSI) reported third-quarter sales of $416.2 million, up 8.4% year over year, and net income of $42.3 million, versus $27.8 million. Nine-month sales were $1,217.0 million, up 8.5%, and net income was $122.1 million versus $90.5 million. Diluted EPS was $0.70 for the quarter and $2.03 for nine months, versus $0.46 and $1.49.
Quarterly therapeutic and foundational sales rose 14.0% and 5.7%. Gross profit as a percentage of sales was 48.2% in the quarter versus 48.5%, and 49.4% for nine months versus 48.4%. Nine-month operating cash flow was $175.2 million versus $198.9 million; cash, cash equivalents and restricted cash were $505.8 million at September 30, 2026.
Merit acquired View Point Medical on April 1, 2026, for $90 million plus $2.8 million in working-capital and other cash adjustments. Two deferred payments of $25 million each are due on the first and second anniversaries and may be accelerated if specified sales targets are met. Merit sold the DualCap product line for $28 million, recording a $12.5 million pretax gain. On October 13, 2026, Merit acquired Solo Pace for $45 million upfront, subject to customary adjustments, and settled $2.5 million of principal and accrued interest on loans it had issued.
Merit Medical Systems, Inc. (MMSI) reported third-quarter 2026 revenue of $416.244 million, up 8.4% year over year. GAAP net income was $42.311 million, compared with $27.755 million a year earlier, and diluted EPS was $0.70 versus $0.46. Non-GAAP operating income and non-GAAP EPS increased 17% and 22%, respectively. Organic constant-currency revenue growth, excluding the strategic divestiture, was 9%.
Merit updated full-year 2026 guidance to revenue of $1.635 billion to $1.642 billion and non-GAAP EPS of $4.33 to $4.37. The outlook is stated absent potential impacts from later trade actions, material acquisitions, non-recurring transactions, and other factors beyond current expectations. Merit paid approximately $45 million on October 13, 2026, for Solo Pace’s remaining equity. The acquisition is projected to be slightly accretive to non-GAAP net income and EPS in 2027, slightly dilutive to GAAP net income and EPS in 2027, and accretive thereafter. Nine-month operating cash flow was $175.230 million, compared with $198.861 million in 2025.
MERIT MEDICAL SYSTEMS INC (symbol: MMSI) is the issuer of record for a Form 4 filing submitted to the SEC. Lewis Sheri reported acquisition or exercise transactions in this Form 4 filing.
MERIT MEDICAL SYSTEMS INC (MMSI) reported that Sheri Lewis, EVP of Global Operations, received a grant of 8,371 restricted stock units (RSUs) of common stock on September 4, 2026 under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. The RSUs vest in three equal annual installments on each anniversary of the award date, subject to her continued service, and her directly held common stock position reported after this grant is 8,371 shares.
MERIT MEDICAL SYSTEMS INC (MMSI) filed an initial insider ownership report for Sheri Lewis, who serves as EVP of Global Operations. This Form 3 filing establishes her status as a company officer subject to SEC insider reporting rules. No equity holdings or transactions are detailed in this filing.
MERIT MEDICAL SYSTEMS INC (MMSI) reported that Chief Operating Officer Neil W. Peterson sold 7,500 shares of common stock on 2026-08-24 in an open-market transaction at a weighted average price of $90.448 per share, with individual trades ranging from $90.43 to $90.53. Following this sale, he directly holds 18,051 common shares. He also holds non-qualified stock options covering 25,000 underlying shares at an exercise price of $68.33, vesting in 25% annual installments beginning 08/19/2022, and options over 13,576 underlying shares at an exercise price of $70.58, vesting in 25% annual installments beginning 02/28/2024.
MERIT MEDICAL SYSTEMS INC (MMSI) executive Michel J. Voigt, Chief Human Resources Officer, reported a bona fide charitable gift of 650 shares of common stock on 2026-08-24, for no consideration. Following this gift, Voigt directly holds 45,412 common shares and indirectly holds 2,265 shares through a 401(k) plan. Voigt also holds non-qualified stock options over 2,420, 4,046, and 11,076 underlying common shares at exercise prices of $56.25, $65.03, and $70.58, expiring in 2028, 2029, and 2030, respectively.
MERIT MEDICAL SYSTEMS, INC. (MMSI) is the issuer of common stock covered by this notice of proposed sale under Rule 144. Officer Neil W. Peterson plans to sell 7,500 shares of MMSI common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $678,360.00 and 59,710,420 shares outstanding. The approximate date of sale is 08/24/2026. The 7,500 shares were acquired on 03/06/2024 from the issuer as exercised shares for cash. Over the past three months, Peterson has sold 21,449 shares of MMSI common stock for $1,823,165.00.
Merit Medical Systems, Inc. (MMSI) reported a leadership transition in its global operations organization and related executive employment terms. On August 14, 2026, Merit eliminated the Chief Operating Officer role, changing Neil W. Peterson’s title to Senior Advisor; he has given notice to resign as an employee effective March 5, 2027.
Effective August 31, 2026, Merit appointed Sheri Lewis as Executive Vice President of Global Operations. Her employment agreement provides a $600,000 annual base salary, a $400,000 signing bonus, and eligibility for an annual bonus starting in fiscal 2026 with a 60% of base salary target (pro-rated for 2026) and a 200% of base salary maximum, plus participation in the 2026 Equity Incentive Plan.
If Lewis is terminated without cause or resigns for good reason (outside a change of control), she is entitled to Accrued Obligations and a lump sum equal to the greater of one year of base salary or a formula based on her three-week salary rate multiplied by completed years of service (capped at 26 years), along with pro-rated performance stock units. If such a termination occurs in connection with a change of control, she instead receives Accrued Obligations and a lump sum equal to 2x the sum of her then-current base salary and the average of her bonuses for the prior three full fiscal years, plus vesting of target performance stock units.
Merit Medical Systems' chief operating officer Neil W. Peterson reported selling 21,449 shares of common stock on 2026-08-04 at $85.00 per share, leaving 25,551 shares held directly. He also reports non-qualified stock options on 25,000 shares at a $68.33 exercise price and 13,576 shares at $70.58, vesting in 25% annual installments beginning 08/19/2022 and 02/28/2024, respectively.
An affiliate of MMSI has filed a notice of proposed sale of common stock under Form 144. The filing lists up to 21,449 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with trading expected on the NASDAQ on or after August 4, 2026.
The shares relate to equity awards described as Performance Shares and Restricted Stock with grant dates in 2025 and 2026 and individual award amounts of 7,278, 1,027, 10,941, 1,175, and 1,028 shares, respectively.